Cyclacel Pharmaceuti (CYCC)

$7.52 -0.43 (-5.41%)
Market Cap 12.60M
Revenue (ttm) 40,000.00
Net Income (ttm) -11.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28,025.00%
Debt to Equity Ratio 0.00
Volume 161,300
Avg Vol 2,332,701
Day's Range N/A - N/A
Shares Out 1.59M
Stochastic %K 14%
Beta 0.08
Analysts Hold
Price Target $1.00

Company Profile

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

Industry: Biotechnology
Sector: Healthcare
Phone: 60 9 08517 7330
Address:
Level 10, Tower 11 Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
stock_wiz25
stock_wiz25 Aug. 18 at 7:28 PM
$CYCC
1 · Reply
bahjatbern
bahjatbern Aug. 18 at 6:12 PM
$CYCC hahahahahahahahah scam scam scam scam all big share holders left
0 · Reply
Javcueaco
Javcueaco Aug. 18 at 2:30 PM
$CYCC ¿why PPCB up 200%?¿why not $CYCC ?
0 · Reply
Viacheslav45
Viacheslav45 Aug. 18 at 10:39 AM
$CYCC 14
0 · Reply
Viacheslav45
Viacheslav45 Aug. 15 at 5:07 PM
$CYCC Are there any experts here who can predict whether there will be a jump to 14?
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Aug. 14 at 4:42 PM
Food for thought. People trashed $CYCC as a scam and bioturd (which frankly it was) and the company paid $1 million for an Indonesian sanitation company. Shortly thereafter, the stock spiked 1000%. Just goes to show what can happen even to stocks like $CYCC and soon $CYCN on any piece of news.
1 · Reply
bahjatbern
bahjatbern Aug. 13 at 8:31 PM
$CYCC this stock is worthless , not even 1$
0 · Reply
bahjatbern
bahjatbern Aug. 13 at 8:29 PM
$CYCC i will be brave and admit: i have been scammed here , absolutely scam, but that is my fault .zero revenue zero result , CEO is a Malaysian lady with fake medical degree , brought some gangsters with her to set up US branch for their shady Malaysian company . just google here and you will laugh your ass off
0 · Reply
bahjatbern
bahjatbern Aug. 13 at 8:04 PM
$CYCC Dead silence here , where are you all ? waiting till it reach 10 to jump or are you all in vacation
0 · Reply
Marcos211
Marcos211 Aug. 13 at 8:01 PM
Watchers and Volume are picking up rapidly on ticker MTEX ! This could be the next multi - day runner! MTEX moves like a true nano nano floater! Show me some 100K buying candles and this could HALT UP and spike to 15+$ Some will buy now some will chase later! $DTREF $CYCC $AVCTQ $HOLO moving now
2 · Reply
Latest News on CYCC
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 5 days ago

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

CYCCP

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

Aug 4, 2025, 6:50 PM EDT - 14 days ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

CYCCP

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

Jul 15, 2025, 12:17 PM EDT - 4 weeks ago

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

CYCCP

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

Jul 7, 2025, 6:00 AM EDT - 6 weeks ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

CYCCP

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

Jul 7, 2025, 6:00 AM EDT - 6 weeks ago

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

CYCCP

Cyclacel Pharmaceuticals Announces Stock Split

Jul 2, 2025, 9:00 AM EDT - 6 weeks ago

Cyclacel Pharmaceuticals Announces Stock Split

CYCCP

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Jun 20, 2025, 4:30 PM EDT - 2 months ago

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCCP

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Jun 3, 2025, 4:15 PM EDT - 2 months ago

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CYCCP

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 15, 2025, 12:50 AM EDT - 3 months ago

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCCP

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

May 7, 2025, 9:00 AM EDT - 3 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCCP

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

May 6, 2025, 6:00 AM EDT - 3 months ago

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

CYCCP

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Apr 2, 2025, 4:05 PM EDT - 4 months ago

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Mar 24, 2025, 7:30 AM EDT - 5 months ago

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

CYCCP

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Feb 27, 2025, 1:38 PM EST - 6 months ago

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

CYCCP

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Jan 3, 2025, 9:01 AM EST - 8 months ago

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

CYCCP

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Dec 5, 2024, 4:05 PM EST - 9 months ago

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

CYCCP

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 14, 2024, 4:15 PM EST - 9 months ago

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 13, 2024, 12:22 PM EST - 9 months ago

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Nov 12, 2024, 4:45 PM EST - 9 months ago

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Oct 24, 2024, 9:15 AM EDT - 10 months ago

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

CYCCP

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 23, 2024, 9:15 AM EDT - 10 months ago

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 9:15 AM EDT - 11 months ago

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Sep 25, 2024, 9:15 AM EDT - 11 months ago

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

CYCCP

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

CYCCP

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Sep 3, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:18 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Aug 7, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

CYCCP

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Jun 26, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

CYCCP

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:08 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

May 8, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

CYCCP

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

May 2, 2024, 4:30 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

CYCCP

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CYCCP

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Apr 1, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 6:09 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

CYCCP

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 7, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

CYCCP

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Mar 6, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

CYCCP

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Feb 20, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

CYCCP

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Jan 30, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

CYCCP

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jan 8, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

CYCCP

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Jan 2, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

CYCCP

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Dec 22, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

CYCCP

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Dec 18, 2023, 9:00 AM EST - 1 year ago

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

CYCCP

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Dec 12, 2023, 4:05 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Reverse Stock Split

CYCCP

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Nov 30, 2023, 9:15 AM EST - 1 year ago

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

CYCCP

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Nov 28, 2023, 5:15 PM EST - 1 year ago

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:32 PM EST - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

Nov 7, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

CYCCP

stock_wiz25
stock_wiz25 Aug. 18 at 7:28 PM
$CYCC
1 · Reply
bahjatbern
bahjatbern Aug. 18 at 6:12 PM
$CYCC hahahahahahahahah scam scam scam scam all big share holders left
0 · Reply
Javcueaco
Javcueaco Aug. 18 at 2:30 PM
$CYCC ¿why PPCB up 200%?¿why not $CYCC ?
0 · Reply
Viacheslav45
Viacheslav45 Aug. 18 at 10:39 AM
$CYCC 14
0 · Reply
Viacheslav45
Viacheslav45 Aug. 15 at 5:07 PM
$CYCC Are there any experts here who can predict whether there will be a jump to 14?
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Aug. 14 at 4:42 PM
Food for thought. People trashed $CYCC as a scam and bioturd (which frankly it was) and the company paid $1 million for an Indonesian sanitation company. Shortly thereafter, the stock spiked 1000%. Just goes to show what can happen even to stocks like $CYCC and soon $CYCN on any piece of news.
1 · Reply
bahjatbern
bahjatbern Aug. 13 at 8:31 PM
$CYCC this stock is worthless , not even 1$
0 · Reply
bahjatbern
bahjatbern Aug. 13 at 8:29 PM
$CYCC i will be brave and admit: i have been scammed here , absolutely scam, but that is my fault .zero revenue zero result , CEO is a Malaysian lady with fake medical degree , brought some gangsters with her to set up US branch for their shady Malaysian company . just google here and you will laugh your ass off
0 · Reply
bahjatbern
bahjatbern Aug. 13 at 8:04 PM
$CYCC Dead silence here , where are you all ? waiting till it reach 10 to jump or are you all in vacation
0 · Reply
Marcos211
Marcos211 Aug. 13 at 8:01 PM
Watchers and Volume are picking up rapidly on ticker MTEX ! This could be the next multi - day runner! MTEX moves like a true nano nano floater! Show me some 100K buying candles and this could HALT UP and spike to 15+$ Some will buy now some will chase later! $DTREF $CYCC $AVCTQ $HOLO moving now
2 · Reply
bahjatbern
bahjatbern Aug. 13 at 3:29 PM
$CYCC what y all sayn about her ?
0 · Reply
bahjatbern
bahjatbern Aug. 13 at 2:09 PM
$CYCC WOW ,strange , how it is holding its price ? with such weak results
0 · Reply
paulinhosma
paulinhosma Aug. 12 at 9:34 PM
$CYCC Wen moon again?
1 · Reply
bahjatbern
bahjatbern Aug. 12 at 3:49 PM
$CYCC are desperate? yet?
0 · Reply
WallStreetReporter
WallStreetReporter Aug. 12 at 3:06 PM
$ADN $CYCC $VERB $LOBO
0 · Reply
Cankles_McTaco_Tits
Cankles_McTaco_Tits Aug. 11 at 9:12 PM
$IXHL (all in) $CYCC $SAIH $BTOG $NEPH
2 · Reply
Cankles_McTaco_Tits
Cankles_McTaco_Tits Aug. 11 at 2:54 PM
$IXHL and $CYCC look so similar I think they're being manipulated by the same bad actor...
0 · Reply
Alqamr
Alqamr Aug. 11 at 11:15 AM
$CYCC
0 · Reply
Moneytalks4T9R
Moneytalks4T9R Aug. 11 at 8:38 AM
$CYCC she wants to run
0 · Reply
Cankles_McTaco_Tits
Cankles_McTaco_Tits Aug. 9 at 8:43 PM
new week, same mcvalue list... $NEGG new target $IXHL - $2.25 $CYCC - $33.19 $SAIH - $20.70 $BTOG - $1.04 $NEGG - $106.11
0 · Reply
Sw1ngb0t
Sw1ngb0t Aug. 9 at 3:52 PM
$IXHL $CYCC $SAIH $BTOG ....$DOGE.X is going nicely... watch out for a squeeze on $BTOG soon
1 · Reply
JoseGilberto109
JoseGilberto109 Aug. 8 at 11:08 PM
Wow what is happening to SNSE right now!? Seems like ALL volume and momentum are shifting into SNSE!! Could it be the next crazy runner of the day?? Only 500k float on SNSE - Bulls should keep it on watch!! Also watching: $DTREF $CYCC $AVCTQ $HOLO $LKNCY !
3 · Reply